Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Urologix Inc
ULGXUrologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. Address: 14405 21st Avenue North, Minneapolis, MN, United States, 55447
Analytics
Zielpreis von Wall Street
1.5 USDKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen ULGX
Dividenden-Analyse ULGX
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende ULGX
Bewertung der Aktie ULGX
Finanzen ULGX
Ergebnisse | 2019 | Dynamik |